0000950170-23-017183.txt : 20230503 0000950170-23-017183.hdr.sgml : 20230503 20230503161208 ACCESSION NUMBER: 0000950170-23-017183 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STAAR SURGICAL CO CENTRAL INDEX KEY: 0000718937 STANDARD INDUSTRIAL CLASSIFICATION: OPHTHALMIC GOODS [3851] IRS NUMBER: 953797439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1230 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-11634 FILM NUMBER: 23883854 BUSINESS ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 BUSINESS PHONE: 6263037902 MAIL ADDRESS: STREET 1: 1911 WALKER AVE CITY: MONROVIA STATE: CA ZIP: 91016 FORMER COMPANY: FORMER CONFORMED NAME: STAAR SURGICAL COMPANY DATE OF NAME CHANGE: 19920703 10-Q 1 staa-20230331.htm 10-Q 10-Q
two years--12-29one year0000718937Q1falsetwo years0000718937staa:ImplantableCollamerLensesMember2022-12-312023-03-310000718937us-gaap:CommercialPaperMember2022-01-012022-12-300000718937staa:OmnibusPlanMember2022-12-312023-03-310000718937us-gaap:CommonStockMember2022-01-012022-04-010000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-312023-03-310000718937us-gaap:SellingAndMarketingExpenseMember2022-01-012022-04-010000718937country:JPus-gaap:GeographicDistributionForeignMember2022-12-312023-03-310000718937staa:OmnibusPlanMemberus-gaap:EmployeeStockOptionMember2022-12-312023-03-310000718937us-gaap:GeographicConcentrationRiskMemberstaa:CustomerOneMemberus-gaap:SalesRevenueNetMembercountry:CN2022-12-312023-03-310000718937us-gaap:RealEstateMember2023-03-310000718937us-gaap:FurnitureAndFixturesMember2022-12-300000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-04-010000718937country:CNus-gaap:GeographicDistributionForeignMember2022-01-012022-04-010000718937staa:PatentsAndLicensesMember2022-12-300000718937us-gaap:ResearchAndDevelopmentExpenseMember2022-12-312023-03-310000718937staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember2022-12-312023-03-310000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-300000718937us-gaap:GeographicDistributionDomesticMember2022-01-012022-04-010000718937us-gaap:CommercialPaperMember2023-03-310000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000718937us-gaap:RetainedEarningsMember2021-12-310000718937us-gaap:FairValueInputsLevel2Member2022-12-300000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-03-310000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-03-310000718937staa:RestrictedStockAwardsAndRestrictedStockUnitsMember2022-01-012022-04-010000718937country:JPus-gaap:GeographicDistributionForeignMember2022-01-012022-04-010000718937staa:NonEmployeeStockOptionsMember2022-01-012022-04-010000718937us-gaap:CommercialPaperMember2022-12-300000718937us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-12-300000718937us-gaap:GeographicConcentrationRiskMemberstaa:CustomerOneMembercountry:CNus-gaap:AccountsReceivableMember2022-12-312023-03-310000718937us-gaap:SalesRevenueNetMemberstaa:OphthalmicSurgicalProductMemberus-gaap:ProductConcentrationRiskMember2022-12-312023-03-310000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000718937us-gaap:GeographicDistributionForeignMember2022-12-312023-03-310000718937staa:OmnibusPlanMemberus-gaap:RestrictedStockMembersrt:MaximumMember2022-12-312023-03-3100007189372023-03-310000718937us-gaap:RetainedEarningsMember2022-01-012022-04-010000718937staa:ConsignmentSalesMember2022-01-012022-04-010000718937staa:OtherCountriesMemberus-gaap:GeographicDistributionForeignMember2022-01-012022-04-010000718937staa:SwissPensionPlanMember2022-12-312023-03-310000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2022-12-300000718937us-gaap:RealEstateMember2022-12-300000718937us-gaap:ComputerEquipmentMember2022-12-300000718937staa:OmnibusPlanMemberus-gaap:RestrictedStockMember2023-03-310000718937us-gaap:CommonStockMember2022-12-300000718937us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-03-310000718937us-gaap:AdditionalPaidInCapitalMember2023-03-310000718937us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMemberstaa:OtherCountriesMembersrt:MaximumMember2022-12-312023-03-310000718937staa:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember2022-01-012022-04-010000718937us-gaap:PerformanceSharesMember2023-03-310000718937us-gaap:MachineryAndEquipmentMember2022-12-300000718937us-gaap:PerformanceSharesMember2022-12-300000718937us-gaap:GeographicConcentrationRiskMemberstaa:CustomerOneMemberus-gaap:SalesRevenueNetMembercountry:CN2022-01-012022-04-010000718937us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-12-312023-03-310000718937us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-12-300000718937us-gaap:AdditionalPaidInCapitalMember2021-12-310000718937us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-04-010000718937country:CNus-gaap:GeographicDistributionForeignMember2022-12-312023-03-310000718937staa:NonEmployeeStockOptionsMember2022-12-312023-03-310000718937us-gaap:USTreasurySecuritiesMember2023-03-310000718937us-gaap:CommonStockMember2023-03-310000718937us-gaap:CorporateDebtSecuritiesMember2023-03-310000718937us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-03-310000718937us-gaap:RetainedEarningsMember2022-12-300000718937us-gaap:GeographicDistributionDomesticMember2022-12-312023-03-310000718937us-gaap:CertificatesOfDepositMember2022-12-3000007189372022-04-010000718937staa:UnvestedRestrictedStockMember2022-01-012022-04-010000718937us-gaap:FairValueInputsLevel1Member2022-12-300000718937us-gaap:CommonStockMember2022-12-312023-03-310000718937staa:NonConsignmentSalesMember2022-01-012022-04-010000718937us-gaap:SellingAndMarketingExpenseMember2022-12-312023-03-310000718937us-gaap:GeographicConcentrationRiskMemberstaa:CustomerOneMembercountry:CNus-gaap:AccountsReceivableMember2022-01-012022-12-300000718937us-gaap:CommonStockMember2022-04-0100007189372021-12-310000718937us-gaap:PerformanceSharesMember2022-12-312023-03-310000718937us-gaap:CorporateDebtSecuritiesMember2022-12-3000007189372022-01-012022-12-300000718937staa:OtherSurgicalProductsMember2022-12-312023-03-310000718937us-gaap:EmployeeStockOptionMember2022-12-312023-03-310000718937us-gaap:RestrictedStockMember2023-03-310000718937us-gaap:CorporateDebtSecuritiesMember2022-12-312023-03-310000718937us-gaap:AdditionalPaidInCapitalMember2022-01-012022-04-010000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-010000718937srt:MaximumMember2023-03-310000718937us-gaap:RestrictedStockMember2022-12-312023-03-310000718937us-gaap:RestrictedStockUnitsRSUMember2023-03-3100007189372022-01-012022-04-010000718937us-gaap:FairValueInputsLevel2Member2023-03-310000718937us-gaap:USTreasurySecuritiesMember2022-12-312023-03-310000718937us-gaap:RestrictedStockMember2022-12-300000718937us-gaap:CorporateDebtSecuritiesMember2022-01-012022-12-300000718937us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2022-12-300000718937us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-04-010000718937staa:CataractIntraocularLensesMember2022-12-312023-03-310000718937us-gaap:CertificatesOfDepositMember2023-03-310000718937staa:ImplantableCollamerLensesMember2022-01-012022-04-010000718937us-gaap:CostOfSalesMember2022-12-312023-03-310000718937staa:CataractIntraocularLensesMember2022-01-012022-04-010000718937us-gaap:PerformanceSharesMember2022-01-012022-04-010000718937us-gaap:USTreasurySecuritiesMember2022-12-300000718937us-gaap:RetainedEarningsMember2023-03-310000718937us-gaap:AdditionalPaidInCapitalMember2022-04-010000718937us-gaap:OtherCurrentLiabilitiesMember2022-12-300000718937us-gaap:GeneralAndAdministrativeExpenseMembersrt:ScenarioForecastMember2022-12-312023-12-290000718937staa:OmnibusPlanMemberus-gaap:RestrictedStockMembersrt:MinimumMember2022-12-312023-03-3100007189372022-12-312023-03-310000718937us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2022-01-012022-12-300000718937us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-300000718937staa:OtherCountriesMemberus-gaap:GeographicDistributionForeignMember2022-12-312023-03-310000718937staa:OtherSurgicalProductsMember2022-01-012022-04-010000718937us-gaap:CertificatesOfDepositMember2022-01-012022-12-300000718937us-gaap:ComputerEquipmentMember2023-03-310000718937staa:UnvestedRestrictedStockMember2022-12-312023-03-310000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-03-310000718937us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-04-010000718937us-gaap:EmployeeStockOptionMember2022-01-012022-04-010000718937us-gaap:RestrictedStockUnitsRSUMember2022-12-300000718937us-gaap:GeneralAndAdministrativeExpenseMember2022-12-312023-03-310000718937srt:MinimumMember2023-03-310000718937us-gaap:FurnitureAndFixturesMember2023-03-310000718937us-gaap:CostOfSalesMember2022-01-012022-04-010000718937staa:NonConsignmentSalesMember2022-12-312023-03-310000718937staa:RestrictedStockAwardsAndRestrictedStockUnitsMember2022-12-312023-03-310000718937staa:PatentsAndLicensesMember2023-03-3100007189372023-04-280000718937us-gaap:FairValueInputsLevel1Member2023-03-310000718937staa:SwissPensionPlanMember2022-01-012022-04-010000718937us-gaap:RestrictedStockUnitsRSUMember2022-12-312023-03-310000718937us-gaap:USTreasurySecuritiesMember2022-01-012022-12-300000718937us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-300000718937us-gaap:CommonStockMember2021-12-310000718937us-gaap:EmployeeStockOptionMember2022-12-312023-03-310000718937us-gaap:RetainedEarningsMember2022-12-312023-03-310000718937us-gaap:RestrictedStockMember2022-01-012022-04-010000718937us-gaap:RetainedEarningsMember2022-04-010000718937us-gaap:CommercialPaperMember2022-12-312023-03-310000718937staa:ConsignmentSalesMember2022-12-312023-03-310000718937us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasurySecuritiesMember2023-03-310000718937us-gaap:GeographicDistributionForeignMember2022-01-012022-04-010000718937us-gaap:EmployeeStockOptionMember2022-01-012022-04-0100007189372022-12-300000718937us-gaap:CertificatesOfDepositMember2022-12-312023-03-310000718937us-gaap:OtherCurrentLiabilitiesMember2023-03-310000718937us-gaap:MachineryAndEquipmentMember2023-03-310000718937us-gaap:AdditionalPaidInCapitalMember2022-12-300000718937us-gaap:AdditionalPaidInCapitalMember2022-12-312023-03-31staa:Segmentxbrli:purexbrli:sharesstaa:Countryiso4217:USDxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2023

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 0-11634

 

STAAR Surgical Company

(Exact Name of Registrant as Specified in its Charter)

 

Delaware

95-3797439

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer

Identification No.)

25651 Atlantic Ocean Drive
Lake Forest, California

 

92630

(Address of Principal Executive Offices)

(Zip Code)

 

(626) 303-7902

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common

STAA

NASDAQ

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

Emerging growth company

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

The registrant has 48,333,250 shares of common stock, par value $0.01 per share, issued and outstanding as of April 28, 2023.

 


STAAR SURGICAL COMPANY

 

INDEX

 

 

 

 

PAGE

NUMBER

 

 

 

 

PART I – FINANCIAL INFORMATION

 

1

 

 

 

 

ITEM 1

FINANCIAL STATEMENTS

 

1

 

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

16

 

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

21

 

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

 

21

 

 

 

 

PART II – OTHER INFORMATION

 

21

 

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

 

21

 

 

 

 

ITEM 1A.

RISK FACTORS

 

21

 

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

 

22

 

 

 

 

ITEM 5.

OTHER INFORMATION

 

22

 

 

 

 

ITEM 6.

EXHIBITS

 

22

 

 

 


PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts)

(Unaudited)

 

 

 

March 31, 2023

 

 

December 30, 2022

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

89,968

 

 

$

86,480

 

Investments available for sale

 

 

113,879

 

 

 

125,159

 

Accounts receivable trade, net of allowance for credit losses of
   $
43 and $20, respectively

 

 

63,494

 

 

 

62,447

 

Inventories, net

 

 

27,808

 

 

 

24,161

 

Prepayments, deposits and other current assets

 

 

17,722

 

 

 

13,476

 

Total current assets

 

 

312,871

 

 

 

311,723

 

Investments available for sale

 

 

13,445

 

 

 

13,902

 

Property, plant and equipment, net

 

 

53,453

 

 

 

50,921

 

Finance lease right-of-use assets, net

 

 

303

 

 

 

342

 

Operating lease right-of-use assets, net

 

 

31,182

 

 

 

30,270

 

Intangible assets, net

 

 

165

 

 

 

173

 

Goodwill

 

 

1,786

 

 

 

1,786

 

Deferred income taxes

 

 

4,744

 

 

 

4,824

 

Other assets

 

 

956

 

 

 

957

 

Total assets

 

$

418,905

 

 

$

414,898

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

9,102

 

 

$

11,576

 

Obligations under finance leases

 

 

171

 

 

 

169

 

Obligations under operating leases

 

 

3,538

 

 

 

3,524

 

Allowance for sales returns

 

 

5,303

 

 

 

5,706

 

Other current liabilities

 

 

28,949

 

 

 

30,741

 

Total current liabilities

 

 

47,063

 

 

 

51,716

 

Obligations under finance leases

 

 

167

 

 

 

210

 

Obligations under operating leases

 

 

28,030

 

 

 

27,136

 

Deferred income taxes

 

 

1,369

 

 

 

1,489

 

Asset retirement obligations

 

 

218

 

 

 

220

 

Pension liability

 

 

3,134

 

 

 

1,935

 

Total liabilities

 

 

79,981

 

 

 

82,706

 

Commitments and contingencies

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.01 par value; 60,000 shares authorized: 48,331 and
   
48,212 shares issued and outstanding at March 31, 2023 and
   December 30, 2022, respectively

 

 

483

 

 

 

482

 

Additional paid-in capital

 

 

409,303

 

 

 

404,189

 

Accumulated other comprehensive gain (loss)

 

 

(937

)

 

 

156

 

Accumulated deficit

 

 

(69,925

)

 

 

(72,635

)

Total stockholders’ equity

 

 

338,924

 

 

 

332,192

 

Total liabilities and stockholders’ equity

 

$

418,905

 

 

$

414,898

 

 

See accompanying notes to the condensed consolidated financial statements.

1


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share amounts)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31, 2023

 

 

April 1, 2022

 

Net sales

 

$

73,528

 

 

$

63,200

 

Cost of sales

 

 

15,966

 

 

 

13,936

 

Gross profit

 

 

57,562

 

 

 

49,264

 

Selling, general and administrative expenses:

 

 

 

 

 

 

General and administrative

 

 

18,098

 

 

 

11,940

 

Selling and marketing

 

 

26,354

 

 

 

17,270

 

Research and development

 

 

10,310

 

 

 

7,941

 

Total selling, general and administrative expenses

 

 

54,762

 

 

 

37,151

 

Operating income

 

 

2,800

 

 

 

12,113

 

Other income (expense), net:

 

 

 

 

 

 

Interest income (expense), net

 

 

1,822

 

 

 

(6

)

Gain (loss) on foreign currency transactions

 

 

34

 

 

 

(915

)

Royalty income

 

 

 

 

 

273

 

Other income, net

 

 

63

 

 

 

62

 

Total other income (expense), net

 

 

1,919

 

 

 

(586

)

Income before income taxes

 

 

4,719

 

 

 

11,527

 

Provision for income taxes

 

 

2,009

 

 

 

1,925

 

Net income

 

$

2,710

 

 

$

9,602

 

Net income per share:

 

 

 

 

 

 

Basic

 

$

0.06

 

 

$

0.20

 

Diluted

 

$

0.05

 

 

$

0.19

 

Weighted average shares outstanding:

 

 

 

 

 

 

Basic

 

 

48,247

 

 

 

47,755

 

Diluted

 

 

49,500

 

 

 

49,288

 

 

See accompanying notes to the condensed consolidated financial statements.

2


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31, 2023

 

 

April 1, 2022

 

Net income

 

$

2,710

 

 

$

9,602

 

Other comprehensive income (loss):

 

 

 

 

 

 

Defined benefit plans:

 

 

 

 

 

 

Net change in plan assets

 

 

(1,177

)

 

 

4,068

 

Reclassification into other income (expense), net

 

 

(52

)

 

 

52

 

Investments available for sale:

 

 

 

 

 

 

Change in unrealized gain (loss)

 

 

116

 

 

 

 

Reclassification into other income (expense), net

 

 

(2

)

 

 

 

Foreign currency translation gain (loss)

 

 

(129

)

 

 

(1,014

)

Tax effect

 

 

151

 

 

 

(121

)

Other comprehensive income (loss), net of tax

 

 

(1,093

)

 

 

2,985

 

Comprehensive income

 

$

1,617

 

 

$

12,587

 

 

See accompanying notes to the condensed consolidated financial statements.

3


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

Common
Stock Shares

 

 

Common
Stock Par
Value

 

 

Additional
Paid-In
Capital

 

 

Accumulated
Other
Compre-
hensive
Income
(Loss)

 

 

Accumulated
Deficit

 

 

Total

 

Balance, at December 30, 2022

 

 

48,212

 

 

$

482

 

 

$

404,189

 

 

$

156

 

 

$

(72,635

)

 

$

332,192

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,710

 

 

 

2,710

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(1,093

)

 

 

 

 

 

(1,093

)

Common stock issued upon exercise of options

 

 

40

 

 

 

 

 

 

529

 

 

 

 

 

 

 

 

 

529

 

Stock-based compensation

 

 

 

 

 

 

 

 

6,434

 

 

 

 

 

 

 

 

 

6,434

 

Repurchase of employee common stock for taxes withheld

 

 

(31

)

 

 

 

 

 

(1,849

)

 

 

 

 

 

 

 

 

(1,849

)

Vested restricted and performance stock

 

 

110

 

 

 

1

 

 

 

 

 

 

 

 

 

 

 

 

1

 

Balance, at March 31, 2023

 

 

48,331

 

 

$

483

 

 

$

409,303

 

 

$

(937

)

 

$

(69,925

)

 

$

338,924

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at December 31, 2021

 

 

47,716

 

 

$

477

 

 

$

373,519

 

 

$

(4,048

)

 

$

(111,390

)

 

$

258,558

 

Net income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

9,602

 

 

 

9,602

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

2,985

 

 

 

 

 

 

2,985

 

Common stock issued upon exercise of options

 

 

49

 

 

 

1

 

 

 

911

 

 

 

 

 

 

 

 

 

912

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,260

 

 

 

 

 

 

 

 

 

4,260

 

Vested restricted and performance stock

 

 

45

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, at April 1, 2022

 

 

47,810

 

 

$

478

 

 

$

378,690

 

 

$

(1,063

)

 

$

(101,788

)

 

$

276,317

 

 

See accompanying notes to the condensed consolidated financial statements.

4


STAAR SURGICAL COMPANY

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

 

 

Three Months Ended

 

 

 

March 31, 2023

 

 

April 1, 2022

 

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$

2,710

 

 

$

9,602

 

Adjustments to reconcile net income to net cash used in operating activities:

 

 

 

 

 

 

Depreciation of property, plant, and equipment

 

 

1,113

 

 

 

994

 

Amortization of intangibles

 

 

7

 

 

 

8

 

Accretion/Amortization of investments available for sale

 

 

(983

)

 

 

 

Deferred income taxes

 

 

57

 

 

 

 

Change in net pension liability

 

 

(13

)

 

 

41

 

Stock-based compensation expense

 

 

6,065

 

 

 

3,894

 

Provision for sales returns and bad debts

 

 

(377

)

 

 

(194

)

Inventory provision

 

 

614

 

 

 

434

 

Changes in working capital:

 

 

 

 

 

 

Accounts receivable

 

 

(1,110

)

 

 

(3,927

)

Inventories

 

 

(3,920

)

 

 

(1,483

)

Prepayments, deposits, and other current assets

 

 

(4,249

)

 

 

(4,505

)

Accounts payable

 

 

(3,168

)

 

 

2,668

 

Other current liabilities

 

 

(1,840

)

 

 

(12,142

)

Net cash used in operating activities

 

 

(5,094

)

 

 

(4,610

)

Cash flows from investing activities:

 

 

 

 

 

 

Acquisition of property and equipment

 

 

(2,901

)

 

 

(2,539

)

Purchase of investments available for sale

 

 

(27,445

)

 

 

 

Proceeds from sale or maturity of investments available for sale

 

 

40,279

 

 

 

 

Net cash provided by (used in) investing activities

 

 

9,933

 

 

 

(2,539

)

Cash flows from financing activities:

 

 

 

 

 

 

Repayment of finance lease obligations

 

 

(42

)

 

 

(18

)

Repurchase of employee common stock for taxes withheld

 

 

(1,849

)

 

 

 

Proceeds from the exercise of stock options

 

 

529

 

 

 

912

 

Proceeds from vested restricted stock

 

 

1

 

 

 

 

Net cash provided by (used in) financing activities

 

 

(1,361

)

 

 

894

 

Effect of exchange rate changes on cash and cash equivalents

 

 

10

 

 

 

(384

)

Increase (decrease) in cash and cash equivalents

 

 

3,488

 

 

 

(6,639

)

Cash and cash equivalents, at beginning of the period

 

 

86,480

 

 

 

199,706

 

Cash and cash equivalents, at end of the period

 

$

89,968

 

 

$

193,067

 

 

See accompanying notes to the condensed consolidated financial statements.

5


STAAR SURGICAL COMPANY

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (CONTINUED)

 

Note 1 — Basis of Presentation and Significant Accounting Policies

The Condensed Consolidated Financial Statements of the Company present the financial position, results of operations, and cash flows of STAAR Surgical Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in the Comprehensive Financial Statements have been condensed or omitted pursuant to such rules and regulations. The Consolidated Balance Sheet as of December 30, 2022 was derived from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 30, 2022.

The Condensed Consolidated Financial Statements for the three months ended March 31, 2023 and April 1, 2022, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three months ended March 31, 2023 and April 1, 2022, are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

Each of the Company’s fiscal reporting periods ends on the Friday nearest to the quarter ending date and generally consists of 13 weeks. Unless the context indicates otherwise “we,” “us,” the “Company,” and “STAAR” refer to STAAR Surgical Company and its consolidated subsidiaries.

Note 2 — Investments Available for Sale

During the second half of 2022, the Company started to invest its cash in slightly higher yielding securities. Investments available for sale (“AFS”) and the related fair value measurement consisted of the following (dollars in thousands):

 

 

 

March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements

 

 

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

 

Level 1

 

 

Level 2

 

Commercial paper

 

$

34,464

 

 

$

4

 

 

$

(28

)

 

$

34,440

 

 

$

 

 

$

34,440

 

Certificates of deposit

 

 

18,414

 

 

 

3

 

 

 

(42

)

 

 

18,375

 

 

 

 

 

 

18,375

 

U.S. Treasury securities

 

 

24,430

 

 

 

26

 

 

 

(9

)

 

 

24,447

 

 

 

24,447

 

 

 

 

U.S. agency securities

 

 

10,965

 

 

 

15

 

 

 

(2

)

 

 

10,978

 

 

 

 

 

 

10,978

 

Corporate debt securities

 

 

39,342

 

 

 

3

 

 

 

(261

)

 

 

39,084

 

 

 

 

 

 

39,084

 

Total investments AFS

 

$

127,615

 

 

$

51

 

 

$

(342

)

 

$

127,324

 

 

$

24,447

 

 

$

102,877

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 30, 2022

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements

 

 

 

Amortized Cost

 

 

Unrealized Gains

 

 

Unrealized Losses

 

 

Estimated Fair Value

 

 

Level 1

 

 

Level 2

 

Commercial paper

 

$

44,054

 

 

$

11

 

 

$

(62

)

 

$

44,003

 

 

$

 

 

$

44,003

 

Certificates of deposit

 

 

17,355

 

 

 

4

 

 

 

(75

)

 

 

17,284

 

 

 

 

 

 

17,284

 

U.S. Treasury securities

 

 

21,847

 

 

 

3

 

 

 

(15

)

 

 

21,835

 

 

 

21,835

 

 

 

 

U.S. agency securities

 

 

10,688

 

 

 

16

 

 

 

(3

)

 

 

10,701

 

 

 

 

 

 

10,701

 

Corporate debt securities

 

 

45,522

 

 

 

4

 

 

 

(288

)